Kirkland & Ellis, still among the league table leaders in deal value and volume amidst a down year for mergers and acquisitions and for the firm’s practice in that area, got a nice shot in the arm to start Q4 as the firm represented Bristol Myers Squibb (BMS) in its $13.1 billion acquisition of fellow pharmaceutical company MyoKardia on Monday. The latter was represented by Goodwin Procter.

The deal allows BMS to acquire all of the outstanding common stock shares of MyoKardia for $225 per share in cash. The transaction is expected to close later in Q4 of this year. 

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]